[Taipei, Taiwan] – [June 13, 2025]
As the global population continues to age, the pursuit of delaying aging and enhancing quality of life remains a constant endeavor. Today, YC Biotech announced that its groundbreaking anti-aging stem cell clinical trial, commissioned by JY BioMed, is actively progressing at Taipei Medical University Hospital. This marks a significant step forward, signaling a new era of breakthroughs in the anti-aging field.
For a long time, anti-aging research has been a core focus for the scientific and medical communities. Traditional approaches often focus on symptom management. However, this new study zeroes in on the regenerative potential of stem cells, aiming to fundamentally repair cells and tissues damaged by time and truly reverse the signs of aging.
JY BioMed stated that this highly anticipated clinical trial is designed to assess the safety and preliminary effectiveness of its innovative stem cell therapy. The goal is to improve human bodily functions and slow the aging process. We believe the results of this research will breathe new life into the global anti-aging market, offering consumers who seek vitality unprecedented new options.
The CEO of YC Biotech stated, “We deeply understand the universal desire for youth and health. While aging is an unavoidable part of life, we are confident that biotechnology can offer us more possibilities. By thoroughly exploring the mysteries of stem cells, we are developing a groundbreaking therapy that can effectively delay aging and significantly improve quality of life.”
YC Biotech consistently remains at the forefront of technology, dedicated to translating cutting-edge biotechnology into practical applications. We anticipate that through the ongoing clinical trial, this forward-thinking technology can be brought to market in the future, benefiting more people.
